Additionally, there are also core spliceosome inhibitors, such as the case of H3B-8800, a Pladienolide-B derived SF3B1 inhibitor, which specifically targets cancer cells harboring splicing factor mutations [129], which is currently being tested on leukemia and myelodysplastic syndromes, MDS, (NCT02841540) [145]. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.